(prednisolone acetate, neomycin sulfate, polymyxin B
sulfate ophthalmic suspension, USP)
POLY-PRED® (prednisolone acetate, neomycin sulfate, polymyxin B sulfate ophthalmic suspension, USP) is a topical anti-inflammatory/anti-infective combination product for ophthalmic use with a pH of 5.0 - 7.0 and an osmolality of 260-340 mOsm/kg.
A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus; Escherichia coli; Hemophilus influenzae; Klebsiella/ Enterobacter species; Neisseria species; and Pseudomonas aeruginosa.
The product does not provide adequate coverage against: Serratia marcescens; Streptococci, including Streptococcus pneumoniae.
Clinical Trials Related to Poly-Pred (Prednisolone / Neomycin / Polymyxin B Ophthalmic)
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach [Recruiting]
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with
polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose
glucocorticoids ( 5 mg/day of prednisone) as compared to stopping glucocorticoid treatment
entirely (0 mg/day of prednisone)on rates of disease relapse/disease flares.
This study is a novel approach to conducting a randomized clinical trial in the community
setting. This study is being conducted in parallel with a similar study at established
vasculitis institutions. This study will have a patient centric approach to research in
that subjects will be recruited online and through social media and vasculitis support
networks. Participants will be consented online and will receive care through their regular
treating physician so no travel or additional doctor visits are required. Study participants
will consent to the study and complete online questionnaires about their prednisone dose and
about how they are feeling.
Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O) [Not yet recruiting]
The goal of this clinical research study is to learn if adding ofatumumab/rituximab to the
standard combination of DA-EPOCH (dose-adjusted etoposide, prednisone, vincristine, and
cyclophosphamide) can help control the disease in patients with newly diagnosed or
relapsed/refractory Burkitt leukemia. The safety of this drug combination will also be
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN) [Recruiting]
The investigators goal is to evaluate the role of XOLAIRŽ in treatment of Acute
Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of
prednisone for treatment of drug-induced AIN. Currently there is no good treatment for
drug-induced AIN. Prednisone is the standard treatment but is associated with many
side-effects when used long-term and at high doses.
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance [Recruiting]
Transplantation is a good treatment for people with end-stage kidney disease. However,
there is still much to learn about how to best care for the transplanted kidney and keep it
working for a long time.
Unless a person receiving a kidney from someone else takes drugs that reduce immune
function, the kidney will be rejected. Those drugs must be continued life-long and cause
many issues. Therefore, tolerance of the transplanted kidney, without chronic rejection and
without the need for permanent immunosuppressive drug treatment, is a highly desirable goal.
If this can be achieved, it would make "one kidney for life" possible.
The purpose of this study is to find out if the study treatment will allow people to accept
their new kidney and be able to stop taking anti-rejection medications. The study treatment
includes several days of study medications followed by a kidney and bone marrow transplant.
After the transplant, the study treatment will continue with a few more doses of study
medications and then anti-rejection medication is started. After a while, the
anti-rejection medication is slowly stopped. Researchers will examine blood and tissue
samples and try to identify genetic markers for certain conditions like chimerism, response
to therapy, and tolerance.
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [Recruiting]
The subject is invited to take part in this research study because s/he has been diagnosed
with Burkitt lymphoma and/or leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Primary
Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD).
In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists
are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R,
utilizes two major new strategies. First, the treatment approach utilizes continuous
infusion of chemotherapy over four days, instead of being administered over minutes or
hours. Secondly, the doses of some medications involved are increased or decreased based on
how the drugs affect the subject's ability to produce blood cells, which is used as a
measure of how rapidly the body is processing drugs.
Using this approach in adults, researchers have shown improved cure rates in these cancers.
Additionally, the harmful effects experienced by patients has been mild, with mucositis,
severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing
method has never been used in children, and the effectiveness and side effects of this new
method are unknown in children.
The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment
of children with mature B-cell cancers, and to see if we can maintain cure rates (as has
been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in
Page last updated: 2006-05-11